AstraZeneca AZN and Targacept, Inc. TRGT today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a “switch” monotherapy treatment for patients with major depressive disorder who do not respond adequately to initial antidepressant therapy.
This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD. The RENAISSANCE Program is designed to support a New Drug Application filing planned for the second half of 2012 and a Marketing Authorization Application filing in Europe planned for 2015. AstraZeneca and Targacept are co-developing TC-5214.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in